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of streptomycin, ethambutol, terizidone, 
pyrazinamide, and one fluoroquinolone 
(levofloxacin or ofloxacin) be used in cases such 
as these.(1,3) If streptomycin cannot be used, it 
should be replaced with amikacin.(1,2) Patients 
with extensively drug-resistant tuberculosis 
should be referred to a tertiary referral center, 
and individualized salvage drug regimens 
(which include capreomycin, moxifloxacin, para-
aminosalicylic acid, and ethionamide) should be 
used.(3)
In this review article, we describe the 
principal characteristics of each of the drugs 
Introduction
In Brazil, tuberculosis treatment regimens 
have been standardized by the Brazilian 
National Ministry of Health (NMH) since 
1979. According to the latest technical norms 
published by the NMH (in October of 2009),(1) 
and to the guidelines issued by the World Health 
Organization (WHO),(2) patients with bacilli 
resistant to the rifampin-isoniazid combination 
or to the rifampin-isoniazid combination and at 
least one other first-line drug, as well as patients 
in whom the basic regimen fails, are classified 
as having multidrug-resistant tuberculosis. It 
has been proposed that a combination regimen 
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Resumo
Os objetivos principais do tratamento da tuberculose são curar o paciente e minimizar a possibilidade de transmissão 
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Adverse effects). The binding of aminoglycosides 
to plasma proteins is low (approximately 10%). 
Over a 24-h period, 80-98% of the drug is 
excreted, unaltered, by the kidneys (glomerular 
filtration), 1% is excreted in bile, and 1% is 
excreted in feces. The half-life of streptomycin 
is 2-3 h, and the half-life of amikacin is 2 h, 
although the latter can be as long as 86 h in 
patients with kidney failure.(2,10,11)
Central nervous system
The penetration of aminoglycosides into the 
cerebrospinal fluid (CSF) is low, except in cases 
of meningitis.(2,10,11)
Adverse effects
Ototoxicity
The most severe adverse reaction caused by 
aminoglycosides is ototoxicity due to damage to 
cranial nerve VIII, including vestibular damage 
(vertigo, ataxia, and nystagmus) and cochlear 
damage that can lead to hearing loss. The 
risk increases with age, prolonged duration of 
treatment, and high total accumulated dose. 
The risk also increases in patients who use 
aminoglycosides in association with diuretics 
(furosemide and ethacrynic acid), in dehydrated 
patients, and in patients with a history of hearing 
impairment. Vestibular damage is more common 
than is cochlear damage and occurs earlier. In 
addition, vestibular damage is more common 
in patients using streptomycin than in those 
using amikacin. Ototoxicity requires immediate 
discontinuation of the drug.(2,10-13)
Neurotoxicity
Aminoglycosides can cause perioral pares-
thesia immediately after their administration. 
This adverse effect is benign.(2,10,11)
Nephrotoxicity
Aminoglycosides produce renal toxic effects 
due to their accumulation in the renal tubules. 
Such effects are more common in elderly 
individuals and in patients with a history of kidney 
disease. Clinical and laboratory manifestations 
of nephrotoxicity include oliguria, urinary 
casts, proteinuria, and decreased creatinine 
clearance, as well as increased serum levels 
of urea and creatinine. Patients who receive 
that constitute the alternative regimen for 
tuberculosis treatment proposed by the Brazilian 
National Ministry of Health and the Brazilian 
Thoracic Association,(1,3) as well as the relevant 
aspects of the pharmacokinetics of the drugs 
in order to understand the mechanisms of 
interaction and possible adverse effects.
Aminoglycosides (streptomycin, 
amikacin, and kanamycin)
Streptomycin, which was discovered in 1944, 
was the first drug that was effective in treating 
tuberculosis.(4) Kanamycin was synthesized in 
1957. Amikacin is a semi-synthetic compound 
derived from kanamycin and has been used 
since 1972. Aminoglycosides act on extracellular 
bacilli, and their intracellular activity is therefore 
irrelevant. The minimum inhibitory concen-
trations (MICs) of streptomycin, kanamycin, 
and amikacin for Mycobacterium tuberculosis 
are 4-8 µg/mL, 1-8 µg/mL, and 0.5-1.0 µg/mL, 
respectively. These drugs are bactericidal, and 
their effects are concentration-dependent and 
residual, which means that they have a bactericidal 
effect even when their serum concentrations are 
below the MICs.(5-8) Although there have been 
reports of cross-resistance between amikacin 
and kanamycin, there have been no reports of 
such cross-resistance between streptomycin and 
amikacin or kanamycin.(8,9)
Mechanism of action
Aminoglycosides inhibit protein synthesis 
by irreversibly binding to the 30S ribosomal 
subunit of M. tuberculosis, interfering with the 
integrity of the cell membrane. Resistance is due 
to mutations in the rrs gene, which encodes 16S 
ribosomal RNA, and in the rpsL gene, which 
encodes the S12 ribosomal protein gene.(5,9)
Metabolization and excretion
Oral absorption of aminoglycosides is minimal, 
and the drugs are administered parenterally. 
Absorption is complete when aminoglycosides 
are administered i.m., and the serum levels of 
the drugs peak within 30-90 min after their 
administration; however i.m. absorption can be 
slower, requiring successive injections at the same 
site.(2) It is recommended that i.v. administration 
of aminoglycosides be carried out over a period of 
15-30 min in order to reduce the risk of adverse 
effects, such as neuromuscular blockade (see also 
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with a creatinine clearance < 30 mL/min, 
the dose of the drug should be adjusted to 
12-15 mg • kg−1 • day−1, administered two to 
three times a week. The drug is removed by 
peritoneal dialysis and hemodialysis. In patients 
on peritoneal dialysis or hemodialysis, the dose 
should be adjusted and administered after the 
procedure.(2,10,11)
Interactions
Other drugs
The ototoxicity and nephrotoxicity of 
aminoglycosides can be potentiated by 
concomitant administration of amphotericin 
B, vancomycin, cephalosporin, cisplatin, and 
loop diuretics (ethacrynic acid and furosemide). 
Aminoglycosides can themselves potentiate 
the effects of neuromuscular blocking agents. 
Concomitant administration of aminoglycosides 
and neuromuscular blocking agents can cause 
respiratory depression due to respiratory muscle 
weakness. Patients with myasthenia gravis, 
botulism, hypocalcemia, severe hypokalemia, or 
hypomagnesemia are particularly susceptible to 
such adverse effects. The interaction between 
aminoglycosides and neuromuscular blocking 
agents is independent of the order of their 
administration. Patients using aminoglycosides 
should be monitored for the occurrence of 
respiratory depression in the perioperative and 
postoperative periods.(2,4,10,11,17,18)
Fluoroquinolones
Fluoroquinolones have been used as salvage 
drugs in the treatment of tuberculosis since 
1985.(19) However, recent studies involving 
third-generation and fourth-generation 
fluoroquinolones (levofloxacin, moxifloxacin, and 
gatifloxacin) have demonstrated the enormous 
potential of these drugs and, consequently, the 
great interest of the scientific community in using 
these drugs for the treatment of tuberculosis. 
After their administration, fluoroquinolones are 
widely distributed to the body and have the 
remarkable property of reaching the interior 
of the cells, including macrophages, which 
explains the strong effect of these drugs on 
intracellular mycobacteria.(20-22) There is no 
cross-resistance between fluoroquinolones and 
other antituberculosis drugs, and, although 
in vitro studies have reported cross-reactions 
among the different fluoroquinolones,(20-22) 
more than one daily dose of the drug, patients 
under long-term treatment, and patients with 
high total accumulated dose are more likely to 
develop nephrotoxicity. Nephrotoxicity is more 
common in patients using amikacin (occurring 
in 3.4-8.7%) than in those using streptomycin 
(occurring in 2%). Discontinuation of the drug 
is recommended.(2,10,14-16)
Neuromuscular blockade
Aminoglycosides can cause neuromuscular 
blockade, leading to respiratory failure. 
Neuromuscular blockade can occur due to 
rapid i.v. injection of the drug in patients who 
concomitantly use anesthetics or neuromuscular 
blocking agents (curare or succinylcholine) 
or in those who have received massive blood 
transfusions in which citrate is used as an 
anticoagulant. Although calcium salts can 
reduce this effect, mechanical ventilation might 
be necessary.(2,10)
Hypersensitivity
Hypersensitivity is rare in patients treated 
with aminoglycosides. However, there are 
hypersensitivity cross-reactions among the 
different aminoglycosides.(2,10,11)
Use during pregnancy
Aminoglycosides are category D drugs. 
They rapidly cross the placental barrier and are 
contraindicated during pregnancy because they 
can induce ototoxicity and nephrotoxicity in 
neonates.(2,10,11)
Use during breastfeeding
Aminoglycosides should be avoided during 
breastfeeding. Although aminoglycosides are 
poorly absorbed when administered orally, 
changes in the intestinal flora of neonates can 
occur.(2,10,11)
Use in patients with liver failure
Aminoglycosides can be administered at full 
doses. However, patients with severe liver failure 
should be screened for concomitant hepatorenal 
syndrome.(2,10,11)
Use in patients with kidney failure
Aminoglycosides are almost exclusively 
eliminated by the kidney. Therefore, in patients 
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efflux mechanism that removes the drug from 
the interior of the bacterial cell.(20)
Metabolization and excretion
Fluoroquinolones are rapidly absorbed 
after oral administration, and their serum 
levels peak within 1-3 h. The bioavailability 
of fluoroquinolones ranges from 90% for 
moxifloxacin to 99% for levofloxacin. Only a 
small proportion is metabolized in the liver into 
d-ofloxacin, which has a limited bactericidal 
effect. Fluoroquinolones are excreted principally 
by the kidney through tubular secretion or 
glomerular filtration, and 65-80% of the drug is 
eliminated unaltered. A small proportion (4-8%) 
is excreted in bile and feces. Moxifloxacin, 
however, is metabolized in the liver, and 60% of 
the drug is excreted in bile, 45% being excreted 
unaltered (25% in urine and 20% in feces). The 
half-life of fluoroquinolones ranges from 4 h for 
ciprofloxacin to 10-13 h for moxifloxacin.(20-22)
Central nervous system
The penetration of fluoroquinolones into the 
CSF is poor. The CSF concentration of levofloxacin 
is at 16-20% of the serum concentration of the 
drug. However, in cases of meningitis, the CSF 
levels of ciprofloxacin and ofloxacin can be as 
high as 40-90% of the plasma levels of these 
drugs.(10,31)
Adverse effects(10,20,32-36)
Gastrointestinal effects
The most common side effects of 
fluoroquinolones are gastrointestinal. Patients 
can present with nausea, vomiting, aerophagy, 
anorexia, abdominal discomfort, and diarrhea. 
Gastrointestinal effects occur in 3-17% of the 
patients. Pseudomembranous colitis is rare.
Central nervous system effects
Dizziness, headache, insomnia, tremors, and 
mood disorders occur in 0.9-11% of patients 
treated with fluoroquinolones. Hallucinations, 
delusions, and convulsions are rare. Greater 
attention should be paid to these effects in 
elderly patients and in those using theophylline 
or nonsteroidal anti-inflammatory drugs 
(NSAIDS).
levofloxacin and moxifloxacin have been used 
even in cases of previous M. tuberculosis 
resistance to ofloxacin.(23,24) Fluoroquinolones 
are bactericidal and show different degrees of 
effectiveness against M. tuberculosis. The most 
effective fluoroquinolones are moxifloxacin and 
gatifloxacin, followed by levofloxacin, ofloxacin, 
and ciprofloxacin.(20,23,25) In vitro, the MICs of 
ciprofloxacin, ofloxacin, levofloxacin, gatiflo-
xacin, and moxifloxacin for M. tuberculosis are 
0.5-4.0 µg/mL, 1.0-2.0 µg/mL, 1.0 µg/mL, 0.20-
0.25 µg/mL, and 0.12-0.50 µg/mL, respectively.
(21,26) Recent studies have shown that ciprofloxacin 
should not be included in the antituberculosis 
regimen.(27) In regions where the prevalence 
of tuberculosis is high, fluoroquinolones 
have been administered as monotherapy for 
the empirical treatment of patients under 
clinical and radiological suspicion of having 
bacterial pneumonia; however, the respiratory 
symptoms can temporarily improve in patients 
with unsuspected or undiagnosed pulmonary 
tuberculosis, thus delaying the diagnosis of 
tuberculosis and selecting fluoroquinolone-
resistant bacilli.(28-30)
Mechanism of action
Fluoroquinolones inhibit M. tuberculosis 
DNA gyrase activity or topoisomerase II activity, 
which regulates DNA topology and is essential 
to the survival of M. tuberculosis. The DNA 
molecule of M. tuberculosis is compacted by 
DNA gyrase and becomes biologically active. 
When fluoroquinolones inhibit this enzyme, the 
DNA molecule stops supercoiling in order to 
occupy a small cellular space for its expression, 
recombination, and replication. Free DNA 
ends induce uncontrolled mRNA synthesis, 
protein synthesis, exonuclease production, and 
chromosome degradation. These factors lead 
to cell death. In vitro, fluoroquinolones also 
inhibit topoisomerase IV; however, this does 
not contribute to the bactericidal effect on 
M. tuberculosis, since this enzyme is absent in the 
bacillus.(20,21) Bacterial resistance occurs rapidly 
when a fluoroquinolone is used as monotherapy 
or when it is included in regimens that failed. 
Three principal mechanisms explain resistance: 
mutations in the DNA gyrase enzyme, which 
becomes immune to the effect of the antibiotic; 
changes in the bacterial cell membrane, which 
becomes impermeable to fluoroquinolones, 
decreasing the diffusion of the drug to the 
interior of the cell; and the existence of an 
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Endocrine effects
Changes in glycemia levels, including 
symptomatic hypoglycemia and, less commonly, 
hyperglycemia, have been reported to occur in 
patients with diabetes who use fluoroquinolones 
in conjunction with oral hypoglycemic agents or 
insulin.
Biochemical effects
Leukopenia and eosinophilia occur in less 
than 1% of the cases, and increased transaminase 
levels occur in 1-3% of the patients. Therapy is 
rarely discontinued due to these changes.
Use during pregnancy
Fluoroquinolones are category C drugs. In 
principle, fluoroquinolones should not be used 
during pregnancy. There is no evidence that the 
incidence of abnormalities is higher in children 
treated with fluoroquinolones. However, 
studies involving animals and ciprofloxacin 
have suggested that there are risks of damage 
to the articular cartilages of the fetus and, 
consequently, of juvenile arthritis and joint 
lesions. Fluoroquinolones should be used 
during pregnancy only when the benefits of 
the treatment outweigh the potential risks. The 
decision to use a fluoroquinolone can be made 
only after clinicians who have considerable 
experience in managing tuberculosis have been 
consulted.(2,10)
Use during breastfeeding
Ofloxacin is excreted in breast milk.(37) There 
are no data regarding breastfeeding and the use 
of levofloxacin or moxifloxacin. Considering the 
potential adverse effects of the drugs on infants, 
the WHO suggests that fluoroquinolones be 
used only in cases in which they are vital to the 
health of the mother.(2,10)
Use in patients with liver failure
Fluoroquinolones can be used without 
restrictions in patients with mild or moderate 
liver failure (Child-Pugh classes A and B). 
However, in cases of severe liver disease (Child-
Pugh class C), as occurs with any other drug, 
patients should be closely monitored, through 
clinical evaluation and laboratory testing.(2,10)
Use in patients with kidney failure
The dose of any given fluoroquinolone 
should be adjusted in patients with kidney 
Skin reactions and allergies
Erythema, pruritus, and skin rash 
occur in 0.4-2.2% of patients treated with 
fluoroquinolones. Phototoxicity can occur 
when patients are exposed to ultraviolet light. 
Urticaria, angioedema, anaphylactic reactions, 
and vasculitis are uncommon.
Musculoskeletal effects
Arthropathy and cartilage erosion have 
been observed in young animals treated with 
fluoroquinolones (especially for prolonged 
periods or at high doses), and the use of 
fluoroquinolones in children is therefore 
restricted. However, the use of fluoroquinolones 
in special situations (e.g., in children with cystic 
fibrosis) has increased. Arthralgia has been 
observed in only 2% of such cases and has 
always been reported to be reversible. Achilles 
tendinopathy and Achilles tendon rupture have 
been reported to occur. These are rare and 
bilateral, occurring in 50% of the cases. These 
are often associated with predisposing factors 
such as previous corticosteroid use, rheumatoid 
arthritis, kidney failure, and hemodialysis.
Cardiovascular effects
In patients treated with fluoroquinolones, 
prolongation of the electrocardiographic 
QT interval can occur, leading to ventricular 
tachycardia, including polymorphic ventricular 
tachycardia (torsades de pointes). This is a 
rare event. Electrocardiographic QT interval 
prolongation is dose-dependent. Patients with 
kidney failure, liver failure, cardiomyopathy, 
hypomagnesemia, or hypokalemia, as well as those 
using class IA antiarrhythmic drugs (procainamide 
and quinidine) or class III antiarrhythmic drugs 
(amiodarone and sotalol), together with those 
using terfenadine, erythromycin, cisapride, or 
tricyclic antidepressants, should receive special 
attention.
Urinary tract effects
Interstitial nephritis, characterized by the 
presence of eosinophils and crystals in urine, can 
occur in patients treated with fluoroquinolones. 
These are rare events. However, patients using 
fluoroquinolones who present with dehydration, 
diarrhea, and vomiting should receive appropriate 
fluid supplementation.
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serum levels of fluoroquinolones. Concomitant 
administration of fluoroquinolones and NSAIDS 
can increase central nervous system stimulation 
and the possibility of convulsions.
Cycloserine/terizidone
Cycloserine/terizidone, synthesized in 1952, 
is a structural analogue of D-alanine amino acid, 
a component that is important to the formation 
of the bacterial cell wall. Terizidone results from 
the combination of two cycloserine molecules. 
There is no cross-reaction between cycloserine/
terizidone and other antituberculosis drugs. The 
MIC of cycloserine/terizidone for M. tuberculosis 
is 5-20 mg/mL. At the usual doses, cycloserine/
terizidone has a bacteriostatic effect.(2,5,40,41)
Mechanism of action
Cycloserine/terizidone acts by competition, 
inhibiting the enzymes D-alanyl-D-alanine 
synthetase, alanine racemase, and alanine 
permease, which are indispensable for the 
synthesis of the peptidoglycan that confers 
rigidity and stability to the M. tuberculosis 
cell membrane. Although the mechanisms 
of M. tuberculosis resistance to cycloserine/
terizidone have yet to be fully clarified, it is 
presumably due to genetic mutations in the 
aforementioned enzymes.(2,5,41)
Metabolization and excretion
Cycloserine/terizidone is rapidly absorbed 
after oral administration, and the bioavailability 
of the drug ranges from 70% to 90%. Plasma 
levels of the drug peak within 3-4 after ingestion. 
The half-life of cycloserine/terizidone is 10 h. 
The drug does not bind to plasma proteins. Only 
a small proportion of cycloserine/terizidone is 
metabolized in the liver. Most of the dose (70%) 
is excreted by the kidney, unaltered, within 72 h. 
A small proportion of the drug is excreted in 
feces.(2,10,41)
Central nervous system
The CSF and serum concentrations of 
cycloserine/terizidone are similar.(10)
Adverse effects
Central nervous system effects
Cycloserine/terizidone has neurological 
adverse effects (headache, vertigo, dysarthria, 
failure. The WHO suggests that, in patients 
with kidney failure and creatinine clearance 
< 30 mL/min, the dose of ofloxacin be adjusted 
to 600-800 mg, administered three times a 
week, and the dose of levofloxacin be adjusted 
to 750-1,000 mg, administered three times a 
week. It is not necessary to adjust the dose of 
moxifloxacin. Fluoroquinolones are not removed 
by peritoneal dialysis or hemodialysis.(33)
Interactions(2,34,35,38,39)
Foods
Foods, with the exception of dairy products 
with a high concentration of calcium, do not 
interfere with the absorption of ofloxacin, 
levofloxacin, or moxifloxacin, as they do with the 
absorption of other fluoroquinolones. Patients 
using ciprofloxacin should be instructed to avoid 
excessive use of foods with high caffeine content, 
since ciprofloxacin inhibits the cytochrome P450 
system, thereby reducing caffeine clearance.
Antacids
Antacids containing calcium, aluminum, 
or magnesium interfere with the absorption 
and concentration of fluoroquinolones. 
Sucralfate inhibits the absorption of the drugs. 
Fluoroquinolones should not be adminis te re d 
until 2 h after the use of antacids. The adminis-
tration of H2 receptor blockers does not interfere 
with the absorption of fluoroquinolones.
Other drugs
Vitamin supplements containing zinc or iron 
interfere with the gastrointestinal absorption of 
fluoroquinolones. Fluoroquinolones can inhibit 
numerous cytochrome P450 subfamilies, which 
increases the plasma concentrations of drugs 
that are metabolized via the cytochrome P450 
system. Fluoroquinolones increase the serum 
levels of theophylline, glibenclamide, and 
cyclosporine, as well as increasing the effect 
of oral anticoagulants. Third-generation and 
fourth-generation fluoroquinolones (levofloxacin 
and moxifloxacin) do not inhibit the cytochrome 
P450 enzyme system and therefore do not interact 
with the aforementioned drugs. However, when 
a fluoroquinolone is concomitantly administered 
with oral anticoagulants, the international 
normalized ratio should be closely monitored. 
Probenecid and cimetidine can increase the 
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breastfeeding. Infants exposed to cycloserine/
terizidone must receive supplemental doses of 
pyridoxine.(2,10,42,44)
Use in patients with liver failure
In patients with liver failure, cycloserine/
terizidone can be used without precautions, 
except in patients with hepatitis due to alcoholism 
or in those at a high risk for convulsions.(2,10)
Use in patients with kidney failure
The dose of cycloserine/terizidone 
should be adjusted in patients with kidney 
failure. In patients with creatinine clearance 
< 30 mL/min, the recommended dose is 
250 mg/day or 500 mg three times a week. These 
doses are not well-established. Patients should 
be closely monitored for signs of neurotoxicity.
(2,10,42) Hemodialysis removes 56% of the drug, 
and patients on hemodialysis should receive 
cycloserine/terizidone after the procedure, at 
a dose of 500 mg administered three times a 
week.(45)
Interactions
Foods
Foods increase the time required for 
cycloserine/terizidone to be absorbed by 
3.5 times, and there can be a 35% reduction in 
the maximum concentration of the drug. Orange 
juice (and probably other acidic beverages) 
reduces the maximum concentration of the 
drug by 15%. Whenever possible, the drug 
should be ingested with water, well before or 
after meals.(46)
Antacids
Antacids do not significantly interfere with 
the absorption and concentration of cycloserine/
terizidone.(46)
Other drugs
There is evidence that combining cycloserine/
terizidone with ethionamide and isoniazid can 
potentiate the neurotoxic effects. Cycloserine/
terizidone can increase the serum levels of 
phenytoin and oral anticoagulants, as well as 
decreasing those of pyridoxine. In patients using 
anticonvulsants and neuroleptics, the dose 
of cycloserine/terizidone should be adjusted. 
somnolence, convulsion, mental confusion, and 
memory deficit) and psychiatric adverse effects 
(psychotic states with catatonic, paranoid, and 
depressive reactions, with a risk of suicide) that 
occur especially when the daily dose is higher 
than 500 mg or when cycloserine/terizidone is 
concomitantly administered with other neurotoxic 
drugs, such as isoniazid and ethionamide. Cases 
of peripheral neuropathy and changes in the 
pressure and quantity of proteins in the CSF have 
been described. The administration of pyridoxine 
can aid in preventing the neurotoxic effects, the 
recommended dose being 100-200 mg/day. 
Patients with a history of epilepsy, severe mental 
disturbances, suicidal tendencies, or alcoholism 
should be closely monitored when receiving 
cycloserine/terizidone. In cases of convulsive 
seizures caused by cycloserine/terizidone, the 
drug should be temporarily discontinued, 
anticonvulsant therapy should be initiated, and 
cycloserine/terizidone should be reinitiated at 
lower doses. In cases of psychotic symptoms, 
cycloserine/terizidone should be discontinued 
for one to four weeks, and antipsychotic drugs 
should be given until the symptoms have been 
controlled. If necessary, the dose of cycloserine/
terizidone can be reduced, provided that this 
does not interfere with the therapeutic regimen. 
Occasionally, it is necessary to use antipsychotic 
drugs concomitantly with the therapeutic 
regimen for the duration of the treatment. 
Family members and health care workers should 
be on the alert to detect, in a timely manner, 
personality changes or signs and symptoms of 
depression.(2,10,42,43)
Skin effects
Although rare, skin rash and Stevens-Johnson 
syndrome can occur in patients treated with 
cycloserine/terizidone.(2,42,43)
Use during pregnancy
Cycloserine/terizidone is a category C drug. It 
has no teratogenic effects in laboratory animals. 
Although it is known that cycloserine/terizidone 
crosses the placental barrier, there are no data 
as to whether the drug is safe for the fetus. 
Cycloserine/terizidone should be used only when 
there is no therapeutic alternative.(2,10,42)
Use during breastfeeding
The American Academy of Pediatrics considers 
cycloserine/terizidone to be compatible with 
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Chart 1 - Approach to the secondary effects of the most common antituberculosis drugs, according to the 
symptoms.(57,58,59)
Secondary effects Probable causative 
drug
Control
Minor Continue the treatment and reevaluate the 
doses.
Anorexia, nausea, and abdominal pain Rifampin, 
pyrazinamide, and 
isoniazid
Instruct patients to take the tablets at bedtime 
or after a light meal. Advise patients to take 
the drug slowly, taking small sips of water. If 
the symptoms persist or worsen, or if signs of 
vomiting or bleeding appear, these should be 
considered major effects.
Arthralgia Pyrazinamide Prescribe acetylsalicylic acid, nonsteroidal anti-
inflammatory drug, or paracetamol.
Burning sensation, hypesthesia,  
or tingling in the hands and feet
Isoniazid Prescribe a daily dose of 50-75 mg of 
pyridoxine.
Somnolence Isoniazid Tranquilize patients. Advise patients to take the 
drug at bedtime.
Orange or red urine Rifampin At the initiation of the treatment, patients 
should be told that this often occurs and is to 
be expected.
Flu-like syndrome  
(fever, chills, headache,  
indisposition, and arthralgia)
Rifampin at 
intermittent doses
Patients should be instructed to use rifampin 
daily.
Cutaneous pruritus Isoniazid and rifampin Instruct patients. Prescribe antihistamines.
Hyperuricemia  
(with or without symptoms)
Pyrazinamide Instruct patients to go on a low purine diet and 
prescribe acetylsalicylic acid.
Major  Discontinue the causative drug and perform 
another clinical evaluation.
Skin rash with or without pruritus Streptomycin, 
isoniazid, rifampin, 
and pyrazinamide
Discontinue the drugs.
Hearing loss  
(if the possibility of cerumen impaction 
has been ruled out by otoscopy)
Streptomycin Discontinue streptomycin.
Vertigo and nystagmus Streptomycin Discontinue streptomycin.
Jaundice (if other causes have been 
ruled out) and hepatitis
Rifampin, isoniazid, 
and pyrazinamide
Discontinue the antituberculosis drugs. 
Reinitiate the drugs in sequence.
Confusion  
(suspect drug-induced acute liver 
failure if there is jaundice)
Most antituberculosis 
drugs
Discontinue the drugs and do not reinitiate 
them until the symptoms have disappeared. 
Request liver function tests and a prothrombin 
time test. Reinitiate the drugs in sequence.
Visual disorders  
(if other causes have been ruled out)
Ethambutol Discontinue ethambutol.
Shock, purpura, and acute kidney injury Rifampin Discontinue rifampin.
Oliguria Streptomycin Discontinue streptomycin.
Rhabdomyolysis with myoglobinuria 
and kidney failure
Pyrazinamide Discontinue pyrazinamide.
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Central nervous system
The CSF and plasma levels of ethionamide 
are similar.(2,10,47)
Adverse effects
Gastrointestinal effects
Ethionamide produces intense gastrointestinal 
effects, including a metallic taste in the mouth, 
excessive salivation, nausea, vomiting (commonly 
severe), loss of appetite, and abdominal pain. 
The symptoms improve if the drug is taken at 
mealtime or at bedtime. In some cases, it might 
be necessary to increase the doses progressively 
until the full dose is reached or to use antiemetics 
(or to do both).(2,10,39,42)
Hepatotoxicity
Ethionamide and isoniazid have a similar 
structure. Therefore, the two drugs can cause 
similar side effects. Hepatotoxicity (toxic 
hepatitis) occurs in approximately 4.3% of the 
patients, especially in those with a history of 
liver disease or alcoholism. Liver changes can 
occur up to five months after the initiation of 
treatment with the drug, and it remains unclear 
whether these changes are due to direct toxicity 
or to hypersensitivity. Hepatotoxicity habitually 
resolves when the drug is discontinued.(2,10,39)
Neurotoxicity
Peripheral neuritis, optic neuritis, diplopia, 
irritability, anxiety, depression, hallucinations, 
convulsions, and psychosis have been reported to 
occur in 1-2% of the patients. In patients with a 
history of mental instability, ethionamide should 
be administered with caution. The neurological 
effects can be minimized by administering 
50-100 mg/day of pyridoxine.(2,10,47)
Cardiovascular effects
Postural hypotension can occur in patients 
treated with ethionamide.(43,48)
Endocrine effects
Patients receiving ethionamide can develop 
gynecomastia, alopecia, hypothyroidism, 
impotence, or menorrhagia. Ethionamide makes 
However, due to the potential effect that 
cycloserine/terizidone has on the central nervous 
system, patients should be closely monitored 
for side effects of this drug combination. 
Concomitant use of cycloserine/terizidone and 
fluoroquinolones can worsen the effects on the 
central nervous system. Concomitant use of 
cycloserine/terizidone and alcohol increases the 
risk of convulsions.(2,10,42)
Ethionamide
Ethionamide has been used as a second-
line drug in the treatment of tuberculosis since 
1956. It is an inactive prodrug, the structure of 
which is analogous to that of isoniazid. However, 
there is no cross-resistance to ethionamide and 
isoniazid. Ethionamide needs to be activated by 
the bacterial enzyme EthA (a monooxygenase 
containing flavin adenine dinucleotide, and 
it is NADPH-specific. Ethionamide acts on 
intracellular and extracellular bacilli. The MIC of 
ethionamide for M. tuberculosis is 0.6-2.5 µg/
mL. At the usual doses, ethionamide is bacterio-
static.(5,47)
Mechanism of action
Although ethionamide is similar to isoniazid, 
the former inhibits the activity of the inhA gene 
of M. tuberculosis. Although the mechanisms of 
action are different, the result is the same: the 
two drugs inhibit protein synthesis, preventing 
mycolic acid biosynthesis and affecting 
the bacterial cell membrane. Resistance to 
ethionamide is due to genetic alterations in 
EthA. M. tuberculosis strains that are resistant 
to isoniazid due to alterations in the katG gene 
(catalase/peroxidase enzyme) remain sensitive to 
ethionamide, which indicates that the enzymes 
that are responsible for the activation of isoniazid 
and ethionamide are different.(5,21,47)
Metabolization and excretion
Ethionamide is rapidly and completely 
absorbed when administered orally, and serum 
levels of the drug peak within approximately 1 
h after its administration. Approximately 30% 
of the drug binds to plasma proteins, and the 
bioavailability of the drug is 80%. Ethionamide 
is metabolized in the liver and excreted in urine, 
1-5% being excreted as active drug (unaltered) 
and the remainder being excreted as metabolites. 
The half-life of ethionamide is 2 h.(2,47)
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Antacids
Antacids do not interfere with the absorption 
of ethionamide.(34)
Other drugs
Concomitant use of ethionamide and 
terizidone or isoniazid can potentiate the 
neurotoxic effects (hallucinations, irritability, 
tremors, depression, convulsions, psychosis, 
and peripheral neuropathy). Concomitant use 
of ethionamide and para-aminosalicylic acid 
can increase hepatotoxicity and the possibility 
of hypothyroidism. Concomitant use of 
ethionamide and alcohol can produce psychotic 
reactions.(2,44)
Capreomycin
Capreomycin is a polypeptide antibiotic 
that is obtained from Streptomyces capreolus 
and has been used as an antituberculosis 
drug since 1959. The MIC of capreomycin for 
M. tuberculosis is 10 µg/mL. The chemical 
structure of capreomycin is different from that 
of aminoglycosides. However, capreomycin and 
aminoglycosides are quite similar in terms of their 
antibacterial activity and adverse effects. There 
is no cross-reaction between capreomycin and 
streptomycin; however, there might be a cross-
reaction between capreomycin and certain strains 
resistant to amikacin and kanamycin.(8,52,52)
Mechanism of action
The mechanism of action of capreomycin has 
yet to be fully understood. It is believed that the 
drug is active because it interferes with bacterial 
protein synthesis.(52)
Metabolization and excretion
Capreomycin is not absorbed when taken 
orally. Capreomycin is administered i.m., and 
absorption can be delayed in cases in which the 
same site of application is used repeatedly. Tissue 
distribution has yet to be fully understood. The 
serum levels of capreomycin peak within 1-2 h 
after the administration of the drug. The plasma 
half-life of capreomycin is 4-6 h in patients with 
normal renal function, and it can be as long as 
55 h in patients with kidney failure. Most of the 
dose (50-60%) is excreted through glomerular 
filtration 12 h after administration, and a small 
proportion is excreted via the biliary tract.(2,52)
glycemic control difficult in patients with 
diabetes mellitus.(2,10,49)
Skin reactions
Acne, photosensitivity, and exanthema can 
occur in patients treated with ethionamide. 
Thrombocytopenia and purpura have been 
reported to occur sporadically.(2,10,49)
Use during pregnancy
Ethionamide is a category C drug. It crosses 
the placental barrier. The use of ethionamide 
during pregnancy is controversial. In rodents, 
high doses of ethionamide have been associated 
with teratogenic effects. In humans, two studies 
reviewing 47 cases showed no deleterious effects; 
however, one study reported malformations in 
7 of 23 neonates born to mothers who used 
the drug.(50,51) Ethionamide should be used 
during pregnancy only when the benefits of 
the treatment outweigh the potential risks. The 
decision to use the drug can be made only after 
clinicians who have considerable experience in 
managing tuberculosis have been consulted.
(2,10,47,49)
Use during breastfeeding
There are no data regarding the concentration 
of ethionamide in breast milk. It is advisable 
to avoid the use of ethionamide during 
breastfeeding.(2,39,51)
Use in patients with liver failure
Ethionamide should be used with caution 
and under continuous monitoring in patients 
with liver disease.(2,10)
Use in patients with kidney failure
In patients with creatinine clearance lower 
than 30 mL/min or in those who are on 
hemodialysis, the dose of ethionamide should 
be reduced to 250-500 mg/day. The drug is not 
removed by hemodialysis.(2,10,45)
Interactions
Foods
The effects of foods on the bioavailability of 
ethionamide are minimal.(34)
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agents, aminoglycosides, or polymyxin B due to 
the possibility of additive toxic effects.(2,10)
Para-aminosalicylic acid
Para-aminosalicylic acid has been used as 
an antituberculosis drug since 1946. Beginning 
in 1955 and for nearly 15 years, para-
aminosalicylic acid was considered a first-line 
drug in a combination regimen with isoniazid and 
streptomycin. Para-aminosalicylic acid is used as 
an acid or as a sodium salt. Para-aminosalicylic 
acid is bacteriostatic, and the MIC of the drug for 
M. tuberculosis is 1 µg/mL. Para-aminosalicylic 
acid acts preferentially on extracellular bacilli. 
The drug can currently be administered in 
granules stored in 4-mg envelopes, replacing the 
former 500-mg capsules.(2,5,8,54)
Mechanism of action
The mechanism of action of para-
aminosalicylic acid has yet to be elucidated, and 
it is believed that the mechanism is related to 
interference with bacterial folic acid synthesis 
and inhibition of iron uptake.(2,54)
Metabolization and excretion
Para-aminosalicylic acid is administered 
orally. Para-aminosalicylic acid granules are 
better tolerated than are para-aminosalicylic 
acid capsules. The ingestion of 4 g of para-
aminosalicylic acid granules leads to a maximum 
serum concentration of 20-60 µg/mL after 
4-6 h. The serum levels of para-aminosalicylic 
acid peak within 90-120 min after the ingestion 
of para-aminosalicylic acid capsules. The half-
life of para-aminosalicylic acid is 1 h, and the 
plasma concentrations of the drug after 4-5 h 
are minimal, which justifies the need for doses of 
10-12 g in order to maintain the bacteriostatic 
activity. Para-aminosalicylic acid is metabolized 
in the intestines and liver, via acetylation, into 
N-acetyl-para-aminosalicylic acid. More than 
80% of the drug is excreted by the kidney 
through glomerular filtration and tubular 
secretion.(2,54-56)
Central nervous system
In the presence of meningitis, the CSF 
concentration of para-aminosalicylic acid is 
10-50% of the plasma concentration of the 
drug.(2,10)
Central nervous system
Capreomycin reaches the CSF only in patients 
with meningitis.(2)
Adverse effects
In patients treated with capreomycin, 
common side effects include nephrotoxicity (in 
20-25% of the patients), renal tubular damage, 
proteinuria, electrolyte disturbances, urticaria, 
and maculopapular rash.(2,10)
Ototoxicity (especially vestibular), electrolyte 
changes (decreased serum levels of calcium, 
magnesium, and potassium), pain, edema, and 
abscess at the site of application occasionally 
occur.(2,10)
Use during pregnancy
Capreomycin is a category C drug. In 
adults, capreomycin is less ototoxic than 
are aminoglycosides. However, capreomycin 
should be avoided during pregnancy, since it 
is unknown whether this can be extrapolated 
to the health of the fetus. If it is essential to 
use any given injectable antituberculosis agent 
during pregnancy, capreomycin should be the 
drug of choice.(2,10)
Use during breastfeeding
The concentrations of capreomycin in breast 
milk are unknown. Capreomycin should therefore 
be avoided during pregnancy.(2,10)
Use in patients with liver failure
It is not necessary to adjust the doses of 
capreomycin in patients with liver failure.(10)
Use in patients with kidney failure
Capreomycin should be used with extreme 
caution in patients with creatinine clearance 
< 30 mL/min and in those on hemodialysis. In 
these situations, the dose should be adjusted to 
12-15 mg/kg, administered twice or three times 
a week. The drug is removed by dialysis and 
should be administered after the procedure.(2,10)
Interactions
Other drugs
Capreomycin should not be administered 
concomitantly with neuromuscular blocking 
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Interactions
Foods
Foods increase the absorption of para-
aminosalicylic acid. The drug can be administered 
with water, orange juice, or fatty foods.(46)
Antacids
Antacids do not interfere with the absorption 
of para-aminosalicylic acid.(46)
Other drugs
Digoxin can reduce the absorption of para-
aminosalicylic acid. Ethionamide can increase 
hepatotoxicity and hypothyroidism in patients 
treated with para-aminosalicylic acid. Isoniazid 
increases acetylation, which results in an increase 
in the serum levels of para-aminosalicylic acid. 
Concomitant use of angiotensin-converting 
enzyme inhibitors and para-aminosalicylic 
acid can reduce the antihypertensive effect 
of the latter, and the use of calcium channel 
blockers can increase the anticoagulant effect 
of para-aminosalicylic acid. Concomitant use of 
para-aminosalicylic acid and carbonic anhydrase 
inhibitors potentiate the adverse effects of 
both drugs, and concomitant use of para-
aminosalicylic acid and systemic corticosteroids 
can also increase the number and severity 
of adverse effects, especially gastrointestinal 
effects. Para-aminosalicylic acid can reduce 
the effect of loop diuretics, and, conversely, 
loop diuretics can increase the serum levels of 
para-aminosalicylic acid. With the exception of 
diclofenac, nonselective NSAIDS can increase 
the adverse effects of para-aminosalicylic 
acid. Para-aminosalicylic acid can increase the 
hypoglycemic effects of sulfonylurea, as well as 
increasing the risk of bleeding when administered 
in conjunction with oral anticoagulants, 
thrombolytics, or salicylates.(2,10)
Chart 1 shows the most common adverse 
effects of the principal antituberculosis drugs, 
as well as the recommended practices according 
to the symptoms.(57-59)
Appendix 1 summarizes the interactions 
among antituberculosis drugs.(10,17,38,39,60)
Final considerations
The drugs used for the treatment of 
multidrug-resistant tuberculosis are generally less 
Adverse effects
In patients treated with para-aminosalicylic 
acid, gastrointestinal effects (anorexia, diarrhea, 
nausea, and vomiting) and hypothyroidism, 
the latter occurring especially when para-
aminosalicylic acid is administered concomitantly 
with ethionamide, are common. Thyroid 
function returns to normal when the drug is 
discontinued.(2,10)
Hepatitis (in 0.3-0.5% of the cases), 
allergic reactions (fever, rash, and pruritus), 
hemolytic anemia, agranulocytosis, leukopenia, 
thrombocytopenia, malabsorption syndrome, 
and increased thyroid volume are rare, as are 
cardiovascular adverse effects (pericarditis), 
neurological adverse effects (encephalopathy), 
respiratory adverse effects (eosinophilic 
pneumonia), and ocular adverse effects (optic 
neuritis). Para-aminosalicylic acid should be 
used with caution in patients with glucose-6-
phosphate dehydrogenase deficiency and in 
those who are allergic to aspirin.(2,10,55)
Use during pregnancy
Para-aminosalicylic acid is a category C drug. 
There have been reports of congenital anomalies 
associated with the administration of the drug 
in the first trimester of pregnancy. Therefore, the 
drug should be used in pregnant women only 
when there is no therapeutic alternative.(2,10)
Use during breastfeeding
Para-aminosalicylic acid is secreted in 
breast milk (at 1.4% of the maternal plasma 
concentration of the drug). Para-aminosalicylic 
acid can be used during breastfeeding.(44)
Use in patients with liver failure
Para-aminosalicylic acid should be used with 
caution in patients with liver failure. Hepatic 
enzyme levels should be monitored.(10)
Use in patients with kidney failure
It is not necessary to adjust the doses of 
para-aminosalicylic acid in patients with kidney 
failure. However, the drug can exacerbate 
acidosis and crystalluria in patients with severe 
kidney failure. Sodium para-aminosalicylate can 
also increase blood volume in this situation.(2,10)
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effective, more toxic, and more expensive than 
are the drugs that constitute the basic regimen. 
These characteristics prolong the treatment 
and increase its cost (which can be up to one 
hundred times higher), as well as increasing the 
possibility of adverse events. In addition, these 
characteristics reduce treatment adherence and 
increase treatment failure rates. The relationship 
between the patient and the health care team, 
the early recognition of adverse effects, and the 
knowledge of the pharmacological properties of 
the drugs involved allow professionals to tailor 
their approach to each individual case, thus 
avoiding potentially fatal reactions.
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Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations.  
Part 2: Second-line drugs
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Appendix 1 - Interactions between antituberculosis drugs and foods, as well as between antituberculosis drugs 
and other drugs.(10,17,38,39,60)
Rifampin
Foods (decreased absorption of rifampin)
Para-aminosalicylic acid (decreased absorption of rifampin)
Amiodarone (decreased serum levels of amiodarone)
Oral anticoagulants (decreased serum levels of the anticoagulant)
Contraceptives (decreased serum levels of the contraceptive)
Anticonvulsants (decreased serum levels of the anticonvulsant)
Tricyclic antidepressants (decreased serum levels of the antidepressant)
Antipsychotics (decreased serum levels of the antipsychotic)
Barbiturates and benzodiazepines (decreased serum levels of the barbiturate and benzodiazepine)
Beta blockers (decreased serum levels of the beta blocker)
Cyclosporine (reduced effect of cyclosporine)
Ketoconazole (decreased serum levels of ketoconazole)
Codeine (decreased serum levels of codeine)
Corticosteroids (decreased serum levels of the corticosteroid)
Dapsone (possible decrease in the serum levels of dapsone)
Digital (decreased serum levels of digital)
Diltiazem (decreased serum levels of diltiazem)
Enalapril (decreased serum levels of enalapril)
Statins (decreased serum levels of the statin)
Fluconazole (decreased serum levels of fluconazole)
Haloperidol (decreased serum levels of haloperidol)
Oral hypoglycemic agents (decreased serum levels of the hypoglycemic agent)
Itraconazole (decreased serum levels of itraconazole)
Methadone (decreased serum levels of methadone)
Morphine (decreased serum levels of morphine)
Narcotics and analgesics (decreased serum levels of the narcotic and analgesic)
Propafenone (decreased serum levels of propafenone)
Nifedipine (decreased serum levels of nifedipine)
Quinidine (decreased serum levels of quinidine)
Theophylline (decreased serum levels of theophylline)
Verapamil (decreased serum levels of verapamil)
Isoniazid + ketoconazole (greater hepatotoxicity)
Ethionamide (greater hepatotoxicity)
Phenytoin (greater hepatotoxicity)
Isoniazid (greater hepatotoxicity)
Sulfonamides (greater hepatotoxicity)
Pyrazinamide (greater uric acid excretion)
Efavirenz (decreased serum levels of efavirenz)
Indinavir (decreased serum levels of indinavir)
Lopinavir/Ritonavir (decreased serum levels of lopinavir)
Nelfinavir (decreased serum levels of nelfinavir)
Saquinavir (decreased serum levels of saquinavir)
Zidovudine (decreased serum levels of zidovudine)
Isoniazid
Foods (decreased absorption of isoniazid)
Valproic acid (increased serum concentration of valproic acid)
Antacids/aluminum hydroxide (decreased absorption of isoniazid)
Oral anticoagulants (increased serum concentration of the anticoagulant)
Benzodiazepines (increased serum concentration of the benzodiazepine)
Enflurane (possibility of nephrotoxicity)
Carbamazepine (increased serum concentration of carbamazepine)
Corticosteroids (decreased serum levels of isoniazid)
Ketoconazole (decreased serum concentration of ketoconazole)
Cycloserine (greater neurotoxicity)
Diazepam (increased serum concentration of diazepam)
Disulfiram (possibility of psychotic events)
Phenytoin (increased serum concentration of phenytoin) 
Levodopa (increased serum concentration of catecholamines)
Paracetamol (greater hepatotoxicity)
Rifampin (greater hepatotoxicity)
Theophylline (increased concentration of theophylline)
Cheese and red wine (inhibition of monoamine oxidase) 
Fish (increased concentration of histamine)
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Pyrazinamide
Allopurinol (decreased effect of allopurinol, pyrazinamide increases the serum levels of uric acid)
Colchicine (decreased effect of colchicine, pyrazinamide increases the serum levels of uric acid)
Cyclosporine (decreased serum concentration of cyclosporine)
Ketoconazole (greater hepatotoxicity)
Ethionamide (the adverse effects of ethionamide can increase)
Rifampin (greater hepatotoxicity)
Isoniazid (greater hepatotoxicity)
Ethambutol
Antacids (decreased absorption of ethambutol)
Ethionamide (increased possibility of neurotoxic effects of ethambutol)
Pyrazinamide (increased possibility of hepatotoxicity)
Didanosine and zalcitabine (peripheral neuritis is potentiated)
Aminoglycosides (streptomycin and amikacin) 
Acyclovir (increased possibility of nephrotoxicity)
Ethacrynic acid (increased possibility of ototoxicity)
Amphotericin (increased possibility of nephrotoxicity)
Oral anticoagulants (greater effect of the anticoagulant)
Nonsteroidal anti-inflammatory drugs (increased possibility of ototoxicity and nephrotoxicity)
Capreomycin (increased possibility of ototoxicity and nephrotoxicity)
Cephalosporins (increased possibility of nephrotoxicity)
Cisplatin (increased possibility of nephrotoxicity)
Cyclosporine (increased possibility of nephrotoxicity)
Furosemide (increased possibility of ototoxicity)
Methotrexate (possible increase in the toxicity of methotrexate)
Polymyxins (greater nephrotoxicity)
Vancomycin (greater ototoxicity and nephrotoxicity)
Neuromuscular blocking agents (additive effect)
Ethionamide
Alcohol (increased possibility of psychotic reactions)
Antituberculosis drugs (greater adverse effects)
Isoniazid (temporarily increased serum concentration of isoniazid)
Para-aminosalicylic acid (increased possibility of hypothyroidism)
Terizidone (increased possibility of toxic effects on the central nervous system)
Dapsone (peripheral neuritis is potentiated)
Cycloserine (terizidone) 
Alcohol (increased effects of alcohol and dizziness)
Anticoagulants (increased serum concentration of the anticoagulant)
Ethionamide (possibility of increased toxic effects on the central nervous system)
Phenytoin (increased serum concentration of phenytoin)
Isoniazid (possibility of increased toxic effects on the central nervous system)
Vitamin B6 (increased vitamin B6 clearance)
Fluoroquinolones
Antacids with cations Ca, Mg, Al, and Fe (decreased absorption of fluoroquinolones)
Sucralfate (decreased absorption of fluoroquinolones)
Drugs metabolized by cytochrome P450: cyclosporine, theophylline, warfarin, phenytoin, and sulfonylurea (increased effect of these drugs)
Nonsteroidal anti-inflammatory drugs (increased stimulation of the central nervous system and possibility of convulsions)
Probenecid (increased serum levels of the fluoroquinolone)
Theophylline (increased serum levels of theophylline)
Capreomycin
Neuromuscular blocking agents (increased adverse effects of the two drugs)
Aminoglycosides (increased adverse effects of the two drugs)
Polymyxin B (increased adverse effects of the two drugs)
Para-aminosalicylic acid
Anticoagulants (possibility of increased anticoagulant effect)
Digoxin (decreased serum levels of digoxin)
Corticosteroids (possibility of increased adverse effects of the corticosteroid)
Ethionamide (increased possibility of hypothyroidism and hepatotoxicity)
Isoniazid (possibility of increased serum levels of isoniazid)
Probenecid (increased serum concentration of para-aminosalicylic acid)
Vitamin B12 (decreased serum levels of vitamin B12)
Sulfonylurea (possibility of increasing hypoglycemic effects of sulfonylurea)
